Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Eli Lilly (NYSE: LLY) commands a marketplace capitalization of astir $1.06 trillion, and that valuation was built mostly connected 2 drugs: Mounjaro and Zepbound. Investors speech astir the drugmaker's weight-loss and diabetes franchise constantly. But it's worthy pinning down what these medicines really contribute, and the company's astir caller quarterly study gives a factual answer.

In the archetypal 4th of 2026, Mounjaro and Zepbound generated a combined $12.8 cardinal successful revenue. That was astir two-thirds of Lilly's $19.8 cardinal successful full gross for the play -- a bigger stock than I fishy galore investors realize.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

A franchise inactive accelerating

Mounjaro, Lilly's tirzepatide-based attraction for benignant 2 diabetes, saw worldwide first-quarter gross leap 125% twelvemonth implicit twelvemonth to $8.7 billion. Zepbound, the aforesaid molecule marketed for value loss, grew gross 80% to $4.2 billion.

And the pair's momentum isn't new. The 2 drugs combined for $6.2 cardinal of gross successful the archetypal 4th of 2025, $11.7 cardinal successful the 4th quarter, and $12.8 cardinal successful the astir caller period, meaning the franchise has much than doubled successful a twelvemonth and is inactive climbing 4th by quarter. For full-year 2025, the brace brought successful $36.5 billion, much than fractional of Lilly's $65.2 cardinal successful revenue.

Even much impressive, Mounjaro's maturation complaint is accelerating. It roseate 99% for full-year 2025, 110% successful the 4th quarter, and 125% successful the astir caller quarter. That is bonzer acceleration for a merchandise already generating billions of dollars each quarter.

Lilly's full first-quarter gross roseate 56% twelvemonth implicit year, driven by a 65% summation successful volume, partially offset by a 13% diminution successful realized prices. Growth was global, too, with U.S. gross up 43% and gross extracurricular the U.S. up 81%.

And the surging franchise is showing up connected the bottommost line. Lilly's first-quarter net per stock soared 170% twelvemonth implicit twelvemonth to $8.26, and non-GAAP (adjusted) net per stock roseate 156% to $8.55.

On the spot of the quarter, absorption raised its full-year gross outlook to a scope of $82 cardinal to $85 billion, a $2 cardinal summation from its anterior forecast, and lifted its adjusted earnings-per-share guidance by $2 arsenic well. The caller gross scope implies maturation of astir 28% astatine the midpoint compared with 2025.